Bright Path Pharmaceuticals, LLC (privately held), today announced that ChemWerth’s Chief Scientific Officer, Dr. Xiping Su, has joined the Board of the company following their investment in BPP. Xiping Su, Ph.D., is organic chemistry and ChemWerth’s head of product development. ChemWerth has extensive experience in regulatory affairs having gained approval for 220 Drug Master Files (“DMFs”) submitted with the FDA. ChemWerth is partnering with BPP to identify API targets, prosecute DMP filings and distribute products.
Mr. Quinones acknowledged, “This is a major development for the company, and will are privileged to have this partnership.” Mr. Allen affirmed, “ChemWerth has been a leader in bringing lower-cost, high-quality medicines into the U.S. and Europe. Dr. Su’s experience is unparalleled in our industry.”
About ChemWerth, Inc.
Established in 1982 by Peter Werth, ChemWerth is a full-service generic active pharmaceutical ingredient (API) development and supply company providing cGMP quality APIs to regulated markets worldwide. ChemWerth is a global company headquartered in the United States, with offices in China and India.
Through exclusive development and CMO partnerships, ChemWerth provides expertise in new product selection & development; regulatory & compliance support; and secure supply chain logistics. For more information, please visit www.chemwerth.com.